1. Impaired Thymic Output in Patients with Chronic Hepatitis C Virus Infection. (12th September 2013) Authors: Hartling, H. J.; Gaardbo, J. C.; Ronit, A.; Salem, M.; Laye, M.; Clausen, M. R.; Skogstrand, K.; Gerstoft, J.; Ullum, H.; Nielsen, S. D. Journal: Scandinavian journal of immunology Issue: Volume 78:Number 4(2013:Oct.) Page Start: 378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE. (23rd June 2022) Authors: Clausen, M. R.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; Wu, J.; Elliott, B.; Falchi, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS. (23rd June 2022) Authors: Haujir, A.; Tøstesen, M.; El-Galaly, T. C.; Larsen, T. S.; Starklint, J.; Poulsen, C. B.; Josefsson, P. L.; Clasen-Linde, E.; Dessau-Arp, A.; Clausen, M. R.; Jørgensen, J. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PHASE 3 TRIAL (GCT3013‐05) OF EPCORITAMAB VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (17th June 2021) Authors: Thieblemont, C.; Clausen, M. R.; Balari, A. S.; Zinzani, P. L.; Fox, C. P.; Kim, S. Y.; Vindelov, S. D.; Lugtenburg, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗